Pasithea Therapeutics Presents Initial Clinical Data at European Neurofibromatosis Conference

Pasithea Therapeutics, a clinical-stage biotechnology company, has announced the presentation of initial clinical data from its ongoing Phase 1/1b trial of PAS-004, a next-generation macrocyclic MEK inhibitor, at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

The conference, set to take place from November 12 to 14, 2026, will feature two presentations from Pasithea. The first will be an oral presentation on cutaneous neurofibromas (CN) by Dr. Rebecca Brown from the University of Alabama at Birmingham. This presentation is scheduled for Friday, November 13, from 8:00 to 9:30 (Central European Time) in Lecture Hall 1. The second presentation will be a poster session on plexiform neurofibromas (PN) by Tiago Reis Marques, Pasithea's Chief Executive Officer, on Thursday, November 12.

PAS-004 is being developed for the long-term treatment of chronic diseases, including neurofibromatosis type 1 (NF1)-associated neurofibromas. The ongoing Phase 1/1b clinical trial is testing the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in adult patients with NF1. This is the company's first public disclosure of clinical data from Part A of the trial.

Pasithea's Chief Executive Officer, Tiago Reis Marques, commented, "We are excited to present the initial clinical data from our ongoing Phase 1/1b trial of PAS-004 at the 2026 European Neurofibromatosis Conference. These results represent a significant milestone in our efforts to develop PAS-004 as a potential long-term treatment for NF1-associated neurofibromas."

The company plans to issue a follow-up press release with detailed results at the time of the presentation. Pasithea Therapeutics is focused on the research and development of PAS-004 for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases.